These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18640791)

  • 1. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.
    De Vecchi G; Verderio P; Pizzamiglio S; Manoukian S; Bernard L; Pensotti V; Volorio S; Ravagnani F; Radice P; Peterlongo P
    Cancer Detect Prev; 2008; 32(2):140-3. PubMed ID: 18640791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers.
    Osorio A; Martínez-Delgado B; Pollán M; Cuadros M; Urioste M; Torrenteras C; Melchor L; Díez O; De La Hoya M; Velasco E; González-Sarmiento R; Caldés T; Alonso C; Benítez J
    Hum Mutat; 2006 Mar; 27(3):242-8. PubMed ID: 16419081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer.
    Trifa F; Karray-Chouayekh S; Mabrouk I; Baccouche S; Khabir A; Sellami-Boudawara T; Gargouri A; Mokdad-Gargouri R
    Cancer Epidemiol; 2010 Apr; 34(2):184-8. PubMed ID: 20233677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
    Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression.
    De Feo E; Persiani R; La Greca A; Amore R; Arzani D; Rausei S; D'Ugo D; Magistrelli P; van Duijn CM; Ricciardi G; Boccia S
    Mutat Res; 2009 Apr; 675(1-2):60-5. PubMed ID: 19386249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort.
    Freedman ML; Penney KL; Stram DO; Le Marchand L; Hirschhorn JN; Kolonel LN; Altshuler D; Henderson BE; Haiman CA
    Hum Mol Genet; 2004 Oct; 13(20):2431-41. PubMed ID: 15317758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
    Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of multiplex PCR with histopathologic features for detection of familial breast cancer in formalin-fixed, paraffin-embedded histologic specimens.
    Rassi H; Houshmand M; Hashemi M; Majidzadeh K; Akbari MH; Panahi MS
    Tsitol Genet; 2008; 42(2):55-62. PubMed ID: 18630122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 genotypes and haplotypes associated with risk of breast cancer.
    Buyru N; Altinisik J; Demokan S; Dalay N
    Cancer Detect Prev; 2007; 31(3):207-13. PubMed ID: 17574348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
    Khoury-Shakour S; Lejbkowicz F; Barnett-Griness O; Tamir A; Pinchev M; Rennert G
    Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
    Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
    Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Numerous high-risk epithelial lesions in familial breast cancer.
    Hoogerbrugge N; Bult P; Bonenkamp JJ; Ligtenberg MJ; Kiemeney LA; de Hullu JA; Boetes C; Niermeijer MF; Brunner HG
    Eur J Cancer; 2006 Oct; 42(15):2492-8. PubMed ID: 16908132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.
    Beetstra S; Suthers G; Dhillon V; Salisbury C; Turner J; Altree M; McKinnon R; Fenech M
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2565-71. PubMed ID: 18842997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptive use and BRCA penetrance: a case-only study.
    Pasanisi P; Hédelin G; Berrino J; Chang-Claude J; Hermann S; Steel M; Haites N; Hart J; Peled R; Gafà L; Leggio L; Traina A; Amodio R; Primic-Zakelj M; Zadnik V; Veidebaum T; Tekkel M; Berrino F
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2107-13. PubMed ID: 19549808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.
    Nordgard SH; Ritchie MD; Jensrud SD; Motsinger AA; Alnaes GI; Lemmon G; Berg M; Geisler S; Moore JH; Lønning PE; Børresen-Dale AL; Kristensen VN
    Pharmacogenet Genomics; 2007 Feb; 17(2):127-36. PubMed ID: 17301692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.
    Osorio A; Pollán M; Pita G; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Preisler-Adams S; Niederacher D; Hofmann W; Gadzicki D; Jakubowska A; Hamann U; Lubinski J; Toloczko-Grabarek A; Cybulski C; Debniak T; Llort G; Yannoukakos D; Díez O; Peissel B; Peterlongo P; Radice P; Heikkinen T; Nevanlinna H; Mai PL; Loud JT; McGuffog L; Antoniou AC; Benitez J;
    Br J Cancer; 2008 Sep; 99(6):974-7. PubMed ID: 18781154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.
    Cavallone L; Arcand SL; Maugard C; Ghadirian P; Mes-Masson AM; Provencher D; Tonin PN
    BMC Cancer; 2008 Apr; 8():96. PubMed ID: 18402691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.